Gemcitabine and pemetrexed administered in rapid sequence as front-line chemotherapy for advanced non-small-cell lung cancer: A phase II clinical trial

Annals of Oncology

Volumn 20, Issue 5, 2009, Pages 850-856

  West, Howard L ^a   Wakelee, H A ^b   Perry, M C ^c   Belt, R J ^d   Chen, R ^e   Obasaju, C ^e  

^a SWEDISH MEDICAL CENTER   (United States)

^b STANFORD CANCER INSTITUTE   (United States)

^c UNIVERSITY OF MISSOURI   (United States)

^d Kansas City Chiefs   (United States)

^e ELI LILLY AND COMPANY   (United States)

Author keywords

Gemcitabine; Immediate administration; NSCLC; Pemetrexed; Rapid sequence administration

Indexed keywords

CARBOPLATIN; CISPLATIN; CYANOCOBALAMIN; DEXAMETHASONE; DOCETAXEL; FOLIC ACID; FOLINIC ACID; GEMCITABINE; GRANULOCYTE COLONY STIMULATING FACTOR; NAVELBINE; PACLITAXEL; PEMETREXED; SEROTONIN 3 ANTAGONIST; VINBLASTINE;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; ARTICLE; ASTHENIA; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CHEMOPROPHYLAXIS; CLINICAL TRIAL; CONSTIPATION; DEEP VEIN THROMBOSIS; DEHYDRATION; DIARRHEA; DISEASE COURSE; DOSE RESPONSE; DRUG ACTIVITY; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG ERUPTION; DRUG FATALITY; DRUG RESPONSE; DRUG WITHDRAWAL; DYSPNEA; ERYTHROCYTE TRANSFUSION; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HISTOPATHOLOGY; HUMAN; HYPERGLYCEMIA; HYPOXIA; INCIDENCE; LUNG NON SMALL CELL CANCER; LUNG RESECTION; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OPEN STUDY; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PLEURA EFFUSION; PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RASH; STOMATITIS; SURVIVAL TIME; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA; VOMITING;

EID: 65549153695     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdn715     Document Type: Article

References (28)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55: 74-108.
2. Ginsberg RJ, Vokes EE, Rosenzweig K. Cancer of the lung. In Devita VT, Hellman S, Rosenberg SA (eds): Cancer Principles and Practice of Oncology, 6th edition. Philadelphia, PA: Lippincott Williams & Wilkins 2001; 925-983.
3. Schiller JH, Harrington D, Belani CP et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002; 346(2): 92-98.
4. Scagliotti GV, De Marinis F, Rinaldi M et al. Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer. J Clin Oncol 2002; 20(21): 4285-4291.
5. Georgoulias V, Papadakis E, Alexopoulos A et al. Platinum-based and nonplatinum-based chemotherapy in advanced non-small-cell lung cancer: A randomized multicentre trial. Lancet 2001; 357: 1478-1484.
6. Kosmidis P, Mylonakis N, Nicolaides C et al. Paclitaxel plus carboplatin versus gemcitabine plus paclitaxel in advanced non-small-cell lung cancer: A phase III randomized trial. J Clin Oncol 2002; 20: 3578-3585.
7. Treat J, Belani CP, Edelman MJ et al. A randomized phase III trial of gemcitabine (G) in combination with carboplatin (C) or paclitaxel (P) versus paclitaxel plus carboplatin in advanced (Stage IIIB, IV) non-small cell lung cancer (NSCLC): Update of the Alpha Oncology trial (A1-99002L) [abstract]. Proc Am Soc Clin Oncol 2005; 23: (Abstr 7025).
8. Pfister DF, Johnson DH, Azzoli CG et al. American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003. J Clin Oncol 2004; 22(2): 330-353.
9. Plunkett W, Huang P, Gandhi V. Preclinical characteristics of gemcitabine. Anticancer Drugs 1995; 6 (Suppl 6): 7-13.
10. Mendelsohn LG, Shih C, Chen VJ et al. Enzyme inhibition, polyglutamation, and the effect of LY231514 (MTA) on purine biosynthesis. Semin Oncol 1999; 26 (2 Suppl 6): 42-47.
11. Schultz RM, Chen VJ, Bewley JR et al. Biological activity of the multitargeted antifolate, MTA (LY231514), in human cell lines with different resistance mechanisms to antifolate drugs. Semin Oncol 1999; 26 (2 Suppl 6): 68-73.
12. Teicher BA, Chen V, Shih C et al. Treatment regimens including the multitargeted antifolate LY231514 in human tumor xenografts. Clin Cancer Res 2000; 6(3): 1016-1023.
13. Tonkinson JL, Worzalla JF, Teng CH, Mendelsohn LG. Cell cycle modulation by a multitargeted antifolate, LY231514, increases the cytotoxicity and antitumor activity of gemcitabine in HT29 colon carcinoma. Cancer Res 1999; 59(15): 3671-3676.
14. Adjei AA, Erlichman C, Sloan JA et al. Phase I and pharmacologic study of sequences of gemcitabine and the multitargeted antifolate agent in patients with advanced solid tumors. J Clin Oncol 2000; 18(8): 1748-1757.
15. Monnerat C, Le Chevalier T, Kelly K et al. Phase II study of pemetrexed-gemcitabine combination in patients with advanced-stage non-small cell lung cancer. Clin Cancer Res 2004; 10(16): 5439-5446.
16. Ma CX, Nair S, Thomas S et al. Randomized phase II trial of three schedules of pemetrexed and gemcitabine as front-line therapy for advanced non-small-cell lung cancer. J Clin Oncol 2005; 23(25): 5929-5937.
17. Dy GK, Suri A, Reid JM et al. A phase IB study of the pharmacokinetics of gemcitabine and pemetrexed, when administered in rapid sequence to patients with advanced solid tumors. Cancer Chemother Pharmacol 2005; 55(6): 522-530.
18. Greene FL, Page DL, Fleming ID et al. American Joint Committee on Cancer Staging Manual, 6th edition. Philadelphia, PA: Springer 2002.
19. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31-34.
20. Cancer Therapy Evaluation Program. Common Toxicity Criteria. Version 2.0. DCTD, NCI, NIH, DHHS 1998.
21. Therasse P, Arbuck SG, Eisenhauer EA et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000; 92(3): 205-216.
22. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-481.
23. Peterson P, Park K, Fossella F et al. Is pemetrexed more effective in adenocarcinoma and large cell carcinoma than in squamous cell carcinoma? A retrospective analysis of a phase III trial of pemetrexed vs docetaxel in previously treated patients with advanced non-small cell lung cancer (NSCLC). J Thorac Oncol 2007; 2 (Suppl 4): S851 (Abstr P2-238).
24. Scagliotti GV, Parikh P, von Pawel J et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2008; 26: 3543-3551.
25. Ciuleanu TE, Brodowicz T, Belani CP et al. Maintenance pemetrexed plus best supportive care (BSC) versus placebo plus BSC: A phase III study. J Clin Oncol 2008; 26 (Suppl): 426s (Abstr 8011). Presented at the 44th Annual Meeting of the American Society of Clinical Oncology, Chicago, IL, 30 May to 3 June, 2008.
26. 12 in previously treated patients with non-small cell lung cancer. Clin Cancer Res 2008; 14: 4206-4212.
27. Treat J, Bonomi P, McCleod M et al. Administration of pemetrexed immediately following gemcitabine as front-line therapy in advanced non-small cell lung cancer: A phase II trial. Lung Cancer 2006; 53: 77-83.
28. Dudek AZ, Larson T, McCleod MJ et al. Phase 172 dose escalating study of twice-monthly pemetrexed and gemcitabine in patients with advanced cancer and non-small cell lung cancer. J Thor Oncol 2008; 3(4): 394-399.